Global Docetaxel Market

Docetaxel Comprehensive Study by Type (40 mg/ml, 20 mg/ml, 10 mg/ml), Application (Breast Cancer, Non-Small Cell Lung Cancer, Prostate Cancer, Gastric Adenocarcinoma Cancer, Head and Neck Cancer), End User (Hospitals and Specialty Clinics, Cancer Research and Treatment Centers, Ambulatory Surgery Centers) Players and Region - Global Market Outlook to 2028

Docetaxel Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Docetaxel is an anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. In addition, it has a high stoichiometry of one mole docetaxel per mole tubulin in microtubules and binds to microtubules reversely with maximum affinity. The Docetaxel contains alcohol and may cause intoxication. However, Docetaxel can cause severe side effects if given to a patient whose liver function is abnormal. The global docetaxel market is expected to witness a high growth owing to rise in number of patients suffering with cancer and surge in global geriatric population.This growth is primarily driven by Rise in Number of Patients Suffering With Cancer .

AttributesDetails
Study Period2018-2028
Base Year2022
Forecast Period2023-2028
Volume Unitml
Value UnitUSD (Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


The Pharmaceuticals sector in the region has been increasing at a sustainable rate and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as Sanofi-Aventis (France), Pfizer (United States), Teva Pharmaceutical Industries (Israel), Taj Pharmaceuticals (India), Dr. Reddy's Laboratories (India), Sandoz (Germany), Actavis (United States), Sun pharma (India), Beijing Union Pharmaceutical Factory (China) and Accord Healthcare (United Kingdom), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Key Developments in the Market:
In September 2021, Xiromed LLC the New Jersey-based generic division of Insud Pharmaceuticals has Launches Docetaxel Injection 50mg/mL, generic to Adrucil.
In May 2021, Hikma Pharmaceuticals PLC, the multinational pharmaceutical company, has launched Docetaxel Injection, USP through its US affiliate, Hikma Pharmaceuticals USA Inc. The company has launched 20mg/mL and 80mg/4mL doses.The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.

Regulatory Insights:
FDA's Center for Drug Evaluation and Research (CDER) Center’s best-known job is to evaluate new drugs before they can be sold. CDER's evaluation not only prevents quackery, but also provides doctors and patients the information they need to use medicines wisely. The center ensures that drugs, both brand-name and generic, work correctly and that their health benefits outweigh their known risks.

Influencing Trend:
Increase in Government Expenditures on Healthcare

Market Growth Drivers:
Rise in Number of Patients Suffering With Cancer and Surge in Global Geriatric Population

Challenges:
Lack of Awareness in Developing Region

Restraints:
Adverse Effects Associated With the Use of Cancer Drugs

Opportunities:
Increase in Number of Pipeline Drugs

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mainly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the market's growth. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Data Sources of Docetaxel Market Study

Primary Collection: InMail, LinkedIn Groups, Survey Monkey, Google, and Other professional Forums are some of the mediums utilized to gather primary data through key industry participants and appointees, subject-matter experts, C-level executives of Docetaxel Industry, among others including independent industry consultants, experts, to obtain and verify critical qualitative commentary and opinion and quantitative statistics, to assess future market prospects.

The primary interviews and data collected as per the below protocols:
• By Designation: C-Level, D-Level, Others
• By Company Type: Tier 1, Tier 2, Tier 3

Secondary Data Sources such as Annual reports, Press releases, Analyst meetings, Conference calls, Investor presentations, Management statements, and SEC filings of Docetaxel players along with Regulatory Sites, Association, World bank, etc were used as sources secondary set of data.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Docetaxel Study Sheds Light on
— The Docetaxel Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Docetaxel industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Docetaxel industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • 40 mg/ml
  • 20 mg/ml
  • 10 mg/ml
By Application
  • Breast Cancer
  • Non-Small Cell Lung Cancer
  • Prostate Cancer
  • Gastric Adenocarcinoma Cancer
  • Head and Neck Cancer
By End User
  • Hospitals and Specialty Clinics
  • Cancer Research and Treatment Centers
  • Ambulatory Surgery Centers

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Israel
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rise in Number of Patients Suffering With Cancer
      • 3.2.2. Surge in Global Geriatric Population
    • 3.3. Market Challenges
      • 3.3.1. Lack of Awareness in Developing Region
    • 3.4. Market Trends
      • 3.4.1. Increase in Government Expenditures on Healthcare
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Docetaxel, by Type, Application, End User and Region (value, volume and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Docetaxel (Value)
      • 5.2.1. Global Docetaxel by: Type (Value)
        • 5.2.1.1. 40 mg/ml
        • 5.2.1.2. 20 mg/ml
        • 5.2.1.3. 10 mg/ml
      • 5.2.2. Global Docetaxel by: Application (Value)
        • 5.2.2.1. Breast Cancer
        • 5.2.2.2. Non-Small Cell Lung Cancer
        • 5.2.2.3. Prostate Cancer
        • 5.2.2.4. Gastric Adenocarcinoma Cancer
        • 5.2.2.5. Head and Neck Cancer
      • 5.2.3. Global Docetaxel by: End User (Value)
        • 5.2.3.1. Hospitals and Specialty Clinics
        • 5.2.3.2. Cancer Research and Treatment Centers
        • 5.2.3.3. Ambulatory Surgery Centers
      • 5.2.4. Global Docetaxel Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Israel
          • 5.2.4.4.3. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Docetaxel (Volume)
      • 5.3.1. Global Docetaxel by: Type (Volume)
        • 5.3.1.1. 40 mg/ml
        • 5.3.1.2. 20 mg/ml
        • 5.3.1.3. 10 mg/ml
      • 5.3.2. Global Docetaxel by: Application (Volume)
        • 5.3.2.1. Breast Cancer
        • 5.3.2.2. Non-Small Cell Lung Cancer
        • 5.3.2.3. Prostate Cancer
        • 5.3.2.4. Gastric Adenocarcinoma Cancer
        • 5.3.2.5. Head and Neck Cancer
      • 5.3.3. Global Docetaxel by: End User (Volume)
        • 5.3.3.1. Hospitals and Specialty Clinics
        • 5.3.3.2. Cancer Research and Treatment Centers
        • 5.3.3.3. Ambulatory Surgery Centers
      • 5.3.4. Global Docetaxel Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Israel
          • 5.3.4.4.3. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Docetaxel (Price)
      • 5.4.1. Global Docetaxel by: Type (Price)
  • 6. Docetaxel: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Sanofi-Aventis (France)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Pfizer (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Teva Pharmaceutical Industries (Israel)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Taj Pharmaceuticals (India)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Dr. Reddy's Laboratories (India)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Sandoz (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Actavis (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Sun pharma (India)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Beijing Union Pharmaceutical Factory (China)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Accord Healthcare (United Kingdom)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Docetaxel Sale, by Type, Application, End User and Region (value, volume and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Docetaxel (Value)
      • 7.2.1. Global Docetaxel by: Type (Value)
        • 7.2.1.1. 40 mg/ml
        • 7.2.1.2. 20 mg/ml
        • 7.2.1.3. 10 mg/ml
      • 7.2.2. Global Docetaxel by: Application (Value)
        • 7.2.2.1. Breast Cancer
        • 7.2.2.2. Non-Small Cell Lung Cancer
        • 7.2.2.3. Prostate Cancer
        • 7.2.2.4. Gastric Adenocarcinoma Cancer
        • 7.2.2.5. Head and Neck Cancer
      • 7.2.3. Global Docetaxel by: End User (Value)
        • 7.2.3.1. Hospitals and Specialty Clinics
        • 7.2.3.2. Cancer Research and Treatment Centers
        • 7.2.3.3. Ambulatory Surgery Centers
      • 7.2.4. Global Docetaxel Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Israel
          • 7.2.4.4.3. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Docetaxel (Volume)
      • 7.3.1. Global Docetaxel by: Type (Volume)
        • 7.3.1.1. 40 mg/ml
        • 7.3.1.2. 20 mg/ml
        • 7.3.1.3. 10 mg/ml
      • 7.3.2. Global Docetaxel by: Application (Volume)
        • 7.3.2.1. Breast Cancer
        • 7.3.2.2. Non-Small Cell Lung Cancer
        • 7.3.2.3. Prostate Cancer
        • 7.3.2.4. Gastric Adenocarcinoma Cancer
        • 7.3.2.5. Head and Neck Cancer
      • 7.3.3. Global Docetaxel by: End User (Volume)
        • 7.3.3.1. Hospitals and Specialty Clinics
        • 7.3.3.2. Cancer Research and Treatment Centers
        • 7.3.3.3. Ambulatory Surgery Centers
      • 7.3.4. Global Docetaxel Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Israel
          • 7.3.4.4.3. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Docetaxel (Price)
      • 7.4.1. Global Docetaxel by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Docetaxel: by Type(USD Million)
  • Table 2. Docetaxel 40 mg/ml , by Region USD Million (2017-2022)
  • Table 3. Docetaxel 20 mg/ml , by Region USD Million (2017-2022)
  • Table 4. Docetaxel 10 mg/ml , by Region USD Million (2017-2022)
  • Table 5. Docetaxel: by Application(USD Million)
  • Table 6. Docetaxel Breast Cancer , by Region USD Million (2017-2022)
  • Table 7. Docetaxel Non-Small Cell Lung Cancer , by Region USD Million (2017-2022)
  • Table 8. Docetaxel Prostate Cancer , by Region USD Million (2017-2022)
  • Table 9. Docetaxel Gastric Adenocarcinoma Cancer , by Region USD Million (2017-2022)
  • Table 10. Docetaxel Head and Neck Cancer , by Region USD Million (2017-2022)
  • Table 11. Docetaxel: by End User(USD Million)
  • Table 12. Docetaxel Hospitals and Specialty Clinics , by Region USD Million (2017-2022)
  • Table 13. Docetaxel Cancer Research and Treatment Centers , by Region USD Million (2017-2022)
  • Table 14. Docetaxel Ambulatory Surgery Centers , by Region USD Million (2017-2022)
  • Table 15. South America Docetaxel, by Country USD Million (2017-2022)
  • Table 16. South America Docetaxel, by Type USD Million (2017-2022)
  • Table 17. South America Docetaxel, by Application USD Million (2017-2022)
  • Table 18. South America Docetaxel, by End User USD Million (2017-2022)
  • Table 19. Brazil Docetaxel, by Type USD Million (2017-2022)
  • Table 20. Brazil Docetaxel, by Application USD Million (2017-2022)
  • Table 21. Brazil Docetaxel, by End User USD Million (2017-2022)
  • Table 22. Argentina Docetaxel, by Type USD Million (2017-2022)
  • Table 23. Argentina Docetaxel, by Application USD Million (2017-2022)
  • Table 24. Argentina Docetaxel, by End User USD Million (2017-2022)
  • Table 25. Rest of South America Docetaxel, by Type USD Million (2017-2022)
  • Table 26. Rest of South America Docetaxel, by Application USD Million (2017-2022)
  • Table 27. Rest of South America Docetaxel, by End User USD Million (2017-2022)
  • Table 28. Asia Pacific Docetaxel, by Country USD Million (2017-2022)
  • Table 29. Asia Pacific Docetaxel, by Type USD Million (2017-2022)
  • Table 30. Asia Pacific Docetaxel, by Application USD Million (2017-2022)
  • Table 31. Asia Pacific Docetaxel, by End User USD Million (2017-2022)
  • Table 32. China Docetaxel, by Type USD Million (2017-2022)
  • Table 33. China Docetaxel, by Application USD Million (2017-2022)
  • Table 34. China Docetaxel, by End User USD Million (2017-2022)
  • Table 35. Japan Docetaxel, by Type USD Million (2017-2022)
  • Table 36. Japan Docetaxel, by Application USD Million (2017-2022)
  • Table 37. Japan Docetaxel, by End User USD Million (2017-2022)
  • Table 38. India Docetaxel, by Type USD Million (2017-2022)
  • Table 39. India Docetaxel, by Application USD Million (2017-2022)
  • Table 40. India Docetaxel, by End User USD Million (2017-2022)
  • Table 41. South Korea Docetaxel, by Type USD Million (2017-2022)
  • Table 42. South Korea Docetaxel, by Application USD Million (2017-2022)
  • Table 43. South Korea Docetaxel, by End User USD Million (2017-2022)
  • Table 44. Taiwan Docetaxel, by Type USD Million (2017-2022)
  • Table 45. Taiwan Docetaxel, by Application USD Million (2017-2022)
  • Table 46. Taiwan Docetaxel, by End User USD Million (2017-2022)
  • Table 47. Australia Docetaxel, by Type USD Million (2017-2022)
  • Table 48. Australia Docetaxel, by Application USD Million (2017-2022)
  • Table 49. Australia Docetaxel, by End User USD Million (2017-2022)
  • Table 50. Rest of Asia-Pacific Docetaxel, by Type USD Million (2017-2022)
  • Table 51. Rest of Asia-Pacific Docetaxel, by Application USD Million (2017-2022)
  • Table 52. Rest of Asia-Pacific Docetaxel, by End User USD Million (2017-2022)
  • Table 53. Europe Docetaxel, by Country USD Million (2017-2022)
  • Table 54. Europe Docetaxel, by Type USD Million (2017-2022)
  • Table 55. Europe Docetaxel, by Application USD Million (2017-2022)
  • Table 56. Europe Docetaxel, by End User USD Million (2017-2022)
  • Table 57. Germany Docetaxel, by Type USD Million (2017-2022)
  • Table 58. Germany Docetaxel, by Application USD Million (2017-2022)
  • Table 59. Germany Docetaxel, by End User USD Million (2017-2022)
  • Table 60. France Docetaxel, by Type USD Million (2017-2022)
  • Table 61. France Docetaxel, by Application USD Million (2017-2022)
  • Table 62. France Docetaxel, by End User USD Million (2017-2022)
  • Table 63. Italy Docetaxel, by Type USD Million (2017-2022)
  • Table 64. Italy Docetaxel, by Application USD Million (2017-2022)
  • Table 65. Italy Docetaxel, by End User USD Million (2017-2022)
  • Table 66. United Kingdom Docetaxel, by Type USD Million (2017-2022)
  • Table 67. United Kingdom Docetaxel, by Application USD Million (2017-2022)
  • Table 68. United Kingdom Docetaxel, by End User USD Million (2017-2022)
  • Table 69. Netherlands Docetaxel, by Type USD Million (2017-2022)
  • Table 70. Netherlands Docetaxel, by Application USD Million (2017-2022)
  • Table 71. Netherlands Docetaxel, by End User USD Million (2017-2022)
  • Table 72. Rest of Europe Docetaxel, by Type USD Million (2017-2022)
  • Table 73. Rest of Europe Docetaxel, by Application USD Million (2017-2022)
  • Table 74. Rest of Europe Docetaxel, by End User USD Million (2017-2022)
  • Table 75. MEA Docetaxel, by Country USD Million (2017-2022)
  • Table 76. MEA Docetaxel, by Type USD Million (2017-2022)
  • Table 77. MEA Docetaxel, by Application USD Million (2017-2022)
  • Table 78. MEA Docetaxel, by End User USD Million (2017-2022)
  • Table 79. Middle East Docetaxel, by Type USD Million (2017-2022)
  • Table 80. Middle East Docetaxel, by Application USD Million (2017-2022)
  • Table 81. Middle East Docetaxel, by End User USD Million (2017-2022)
  • Table 82. Israel Docetaxel, by Type USD Million (2017-2022)
  • Table 83. Israel Docetaxel, by Application USD Million (2017-2022)
  • Table 84. Israel Docetaxel, by End User USD Million (2017-2022)
  • Table 85. Africa Docetaxel, by Type USD Million (2017-2022)
  • Table 86. Africa Docetaxel, by Application USD Million (2017-2022)
  • Table 87. Africa Docetaxel, by End User USD Million (2017-2022)
  • Table 88. North America Docetaxel, by Country USD Million (2017-2022)
  • Table 89. North America Docetaxel, by Type USD Million (2017-2022)
  • Table 90. North America Docetaxel, by Application USD Million (2017-2022)
  • Table 91. North America Docetaxel, by End User USD Million (2017-2022)
  • Table 92. United States Docetaxel, by Type USD Million (2017-2022)
  • Table 93. United States Docetaxel, by Application USD Million (2017-2022)
  • Table 94. United States Docetaxel, by End User USD Million (2017-2022)
  • Table 95. Canada Docetaxel, by Type USD Million (2017-2022)
  • Table 96. Canada Docetaxel, by Application USD Million (2017-2022)
  • Table 97. Canada Docetaxel, by End User USD Million (2017-2022)
  • Table 98. Mexico Docetaxel, by Type USD Million (2017-2022)
  • Table 99. Mexico Docetaxel, by Application USD Million (2017-2022)
  • Table 100. Mexico Docetaxel, by End User USD Million (2017-2022)
  • Table 101. Docetaxel Sales: by Type(ml)
  • Table 102. Docetaxel Sales 40 mg/ml , by Region ml (2017-2022)
  • Table 103. Docetaxel Sales 20 mg/ml , by Region ml (2017-2022)
  • Table 104. Docetaxel Sales 10 mg/ml , by Region ml (2017-2022)
  • Table 105. Docetaxel Sales: by Application(ml)
  • Table 106. Docetaxel Sales Breast Cancer , by Region ml (2017-2022)
  • Table 107. Docetaxel Sales Non-Small Cell Lung Cancer , by Region ml (2017-2022)
  • Table 108. Docetaxel Sales Prostate Cancer , by Region ml (2017-2022)
  • Table 109. Docetaxel Sales Gastric Adenocarcinoma Cancer , by Region ml (2017-2022)
  • Table 110. Docetaxel Sales Head and Neck Cancer , by Region ml (2017-2022)
  • Table 111. Docetaxel Sales: by End User(ml)
  • Table 112. Docetaxel Sales Hospitals and Specialty Clinics , by Region ml (2017-2022)
  • Table 113. Docetaxel Sales Cancer Research and Treatment Centers , by Region ml (2017-2022)
  • Table 114. Docetaxel Sales Ambulatory Surgery Centers , by Region ml (2017-2022)
  • Table 115. South America Docetaxel Sales, by Country ml (2017-2022)
  • Table 116. South America Docetaxel Sales, by Type ml (2017-2022)
  • Table 117. South America Docetaxel Sales, by Application ml (2017-2022)
  • Table 118. South America Docetaxel Sales, by End User ml (2017-2022)
  • Table 119. Brazil Docetaxel Sales, by Type ml (2017-2022)
  • Table 120. Brazil Docetaxel Sales, by Application ml (2017-2022)
  • Table 121. Brazil Docetaxel Sales, by End User ml (2017-2022)
  • Table 122. Argentina Docetaxel Sales, by Type ml (2017-2022)
  • Table 123. Argentina Docetaxel Sales, by Application ml (2017-2022)
  • Table 124. Argentina Docetaxel Sales, by End User ml (2017-2022)
  • Table 125. Rest of South America Docetaxel Sales, by Type ml (2017-2022)
  • Table 126. Rest of South America Docetaxel Sales, by Application ml (2017-2022)
  • Table 127. Rest of South America Docetaxel Sales, by End User ml (2017-2022)
  • Table 128. Asia Pacific Docetaxel Sales, by Country ml (2017-2022)
  • Table 129. Asia Pacific Docetaxel Sales, by Type ml (2017-2022)
  • Table 130. Asia Pacific Docetaxel Sales, by Application ml (2017-2022)
  • Table 131. Asia Pacific Docetaxel Sales, by End User ml (2017-2022)
  • Table 132. China Docetaxel Sales, by Type ml (2017-2022)
  • Table 133. China Docetaxel Sales, by Application ml (2017-2022)
  • Table 134. China Docetaxel Sales, by End User ml (2017-2022)
  • Table 135. Japan Docetaxel Sales, by Type ml (2017-2022)
  • Table 136. Japan Docetaxel Sales, by Application ml (2017-2022)
  • Table 137. Japan Docetaxel Sales, by End User ml (2017-2022)
  • Table 138. India Docetaxel Sales, by Type ml (2017-2022)
  • Table 139. India Docetaxel Sales, by Application ml (2017-2022)
  • Table 140. India Docetaxel Sales, by End User ml (2017-2022)
  • Table 141. South Korea Docetaxel Sales, by Type ml (2017-2022)
  • Table 142. South Korea Docetaxel Sales, by Application ml (2017-2022)
  • Table 143. South Korea Docetaxel Sales, by End User ml (2017-2022)
  • Table 144. Taiwan Docetaxel Sales, by Type ml (2017-2022)
  • Table 145. Taiwan Docetaxel Sales, by Application ml (2017-2022)
  • Table 146. Taiwan Docetaxel Sales, by End User ml (2017-2022)
  • Table 147. Australia Docetaxel Sales, by Type ml (2017-2022)
  • Table 148. Australia Docetaxel Sales, by Application ml (2017-2022)
  • Table 149. Australia Docetaxel Sales, by End User ml (2017-2022)
  • Table 150. Rest of Asia-Pacific Docetaxel Sales, by Type ml (2017-2022)
  • Table 151. Rest of Asia-Pacific Docetaxel Sales, by Application ml (2017-2022)
  • Table 152. Rest of Asia-Pacific Docetaxel Sales, by End User ml (2017-2022)
  • Table 153. Europe Docetaxel Sales, by Country ml (2017-2022)
  • Table 154. Europe Docetaxel Sales, by Type ml (2017-2022)
  • Table 155. Europe Docetaxel Sales, by Application ml (2017-2022)
  • Table 156. Europe Docetaxel Sales, by End User ml (2017-2022)
  • Table 157. Germany Docetaxel Sales, by Type ml (2017-2022)
  • Table 158. Germany Docetaxel Sales, by Application ml (2017-2022)
  • Table 159. Germany Docetaxel Sales, by End User ml (2017-2022)
  • Table 160. France Docetaxel Sales, by Type ml (2017-2022)
  • Table 161. France Docetaxel Sales, by Application ml (2017-2022)
  • Table 162. France Docetaxel Sales, by End User ml (2017-2022)
  • Table 163. Italy Docetaxel Sales, by Type ml (2017-2022)
  • Table 164. Italy Docetaxel Sales, by Application ml (2017-2022)
  • Table 165. Italy Docetaxel Sales, by End User ml (2017-2022)
  • Table 166. United Kingdom Docetaxel Sales, by Type ml (2017-2022)
  • Table 167. United Kingdom Docetaxel Sales, by Application ml (2017-2022)
  • Table 168. United Kingdom Docetaxel Sales, by End User ml (2017-2022)
  • Table 169. Netherlands Docetaxel Sales, by Type ml (2017-2022)
  • Table 170. Netherlands Docetaxel Sales, by Application ml (2017-2022)
  • Table 171. Netherlands Docetaxel Sales, by End User ml (2017-2022)
  • Table 172. Rest of Europe Docetaxel Sales, by Type ml (2017-2022)
  • Table 173. Rest of Europe Docetaxel Sales, by Application ml (2017-2022)
  • Table 174. Rest of Europe Docetaxel Sales, by End User ml (2017-2022)
  • Table 175. MEA Docetaxel Sales, by Country ml (2017-2022)
  • Table 176. MEA Docetaxel Sales, by Type ml (2017-2022)
  • Table 177. MEA Docetaxel Sales, by Application ml (2017-2022)
  • Table 178. MEA Docetaxel Sales, by End User ml (2017-2022)
  • Table 179. Middle East Docetaxel Sales, by Type ml (2017-2022)
  • Table 180. Middle East Docetaxel Sales, by Application ml (2017-2022)
  • Table 181. Middle East Docetaxel Sales, by End User ml (2017-2022)
  • Table 182. Israel Docetaxel Sales, by Type ml (2017-2022)
  • Table 183. Israel Docetaxel Sales, by Application ml (2017-2022)
  • Table 184. Israel Docetaxel Sales, by End User ml (2017-2022)
  • Table 185. Africa Docetaxel Sales, by Type ml (2017-2022)
  • Table 186. Africa Docetaxel Sales, by Application ml (2017-2022)
  • Table 187. Africa Docetaxel Sales, by End User ml (2017-2022)
  • Table 188. North America Docetaxel Sales, by Country ml (2017-2022)
  • Table 189. North America Docetaxel Sales, by Type ml (2017-2022)
  • Table 190. North America Docetaxel Sales, by Application ml (2017-2022)
  • Table 191. North America Docetaxel Sales, by End User ml (2017-2022)
  • Table 192. United States Docetaxel Sales, by Type ml (2017-2022)
  • Table 193. United States Docetaxel Sales, by Application ml (2017-2022)
  • Table 194. United States Docetaxel Sales, by End User ml (2017-2022)
  • Table 195. Canada Docetaxel Sales, by Type ml (2017-2022)
  • Table 196. Canada Docetaxel Sales, by Application ml (2017-2022)
  • Table 197. Canada Docetaxel Sales, by End User ml (2017-2022)
  • Table 198. Mexico Docetaxel Sales, by Type ml (2017-2022)
  • Table 199. Mexico Docetaxel Sales, by Application ml (2017-2022)
  • Table 200. Mexico Docetaxel Sales, by End User ml (2017-2022)
  • Table 201. Docetaxel: by Type(USD/Units)
  • Table 202. Company Basic Information, Sales Area and Its Competitors
  • Table 203. Company Basic Information, Sales Area and Its Competitors
  • Table 204. Company Basic Information, Sales Area and Its Competitors
  • Table 205. Company Basic Information, Sales Area and Its Competitors
  • Table 206. Company Basic Information, Sales Area and Its Competitors
  • Table 207. Company Basic Information, Sales Area and Its Competitors
  • Table 208. Company Basic Information, Sales Area and Its Competitors
  • Table 209. Company Basic Information, Sales Area and Its Competitors
  • Table 210. Company Basic Information, Sales Area and Its Competitors
  • Table 211. Company Basic Information, Sales Area and Its Competitors
  • Table 212. Docetaxel: by Type(USD Million)
  • Table 213. Docetaxel 40 mg/ml , by Region USD Million (2023-2028)
  • Table 214. Docetaxel 20 mg/ml , by Region USD Million (2023-2028)
  • Table 215. Docetaxel 10 mg/ml , by Region USD Million (2023-2028)
  • Table 216. Docetaxel: by Application(USD Million)
  • Table 217. Docetaxel Breast Cancer , by Region USD Million (2023-2028)
  • Table 218. Docetaxel Non-Small Cell Lung Cancer , by Region USD Million (2023-2028)
  • Table 219. Docetaxel Prostate Cancer , by Region USD Million (2023-2028)
  • Table 220. Docetaxel Gastric Adenocarcinoma Cancer , by Region USD Million (2023-2028)
  • Table 221. Docetaxel Head and Neck Cancer , by Region USD Million (2023-2028)
  • Table 222. Docetaxel: by End User(USD Million)
  • Table 223. Docetaxel Hospitals and Specialty Clinics , by Region USD Million (2023-2028)
  • Table 224. Docetaxel Cancer Research and Treatment Centers , by Region USD Million (2023-2028)
  • Table 225. Docetaxel Ambulatory Surgery Centers , by Region USD Million (2023-2028)
  • Table 226. South America Docetaxel, by Country USD Million (2023-2028)
  • Table 227. South America Docetaxel, by Type USD Million (2023-2028)
  • Table 228. South America Docetaxel, by Application USD Million (2023-2028)
  • Table 229. South America Docetaxel, by End User USD Million (2023-2028)
  • Table 230. Brazil Docetaxel, by Type USD Million (2023-2028)
  • Table 231. Brazil Docetaxel, by Application USD Million (2023-2028)
  • Table 232. Brazil Docetaxel, by End User USD Million (2023-2028)
  • Table 233. Argentina Docetaxel, by Type USD Million (2023-2028)
  • Table 234. Argentina Docetaxel, by Application USD Million (2023-2028)
  • Table 235. Argentina Docetaxel, by End User USD Million (2023-2028)
  • Table 236. Rest of South America Docetaxel, by Type USD Million (2023-2028)
  • Table 237. Rest of South America Docetaxel, by Application USD Million (2023-2028)
  • Table 238. Rest of South America Docetaxel, by End User USD Million (2023-2028)
  • Table 239. Asia Pacific Docetaxel, by Country USD Million (2023-2028)
  • Table 240. Asia Pacific Docetaxel, by Type USD Million (2023-2028)
  • Table 241. Asia Pacific Docetaxel, by Application USD Million (2023-2028)
  • Table 242. Asia Pacific Docetaxel, by End User USD Million (2023-2028)
  • Table 243. China Docetaxel, by Type USD Million (2023-2028)
  • Table 244. China Docetaxel, by Application USD Million (2023-2028)
  • Table 245. China Docetaxel, by End User USD Million (2023-2028)
  • Table 246. Japan Docetaxel, by Type USD Million (2023-2028)
  • Table 247. Japan Docetaxel, by Application USD Million (2023-2028)
  • Table 248. Japan Docetaxel, by End User USD Million (2023-2028)
  • Table 249. India Docetaxel, by Type USD Million (2023-2028)
  • Table 250. India Docetaxel, by Application USD Million (2023-2028)
  • Table 251. India Docetaxel, by End User USD Million (2023-2028)
  • Table 252. South Korea Docetaxel, by Type USD Million (2023-2028)
  • Table 253. South Korea Docetaxel, by Application USD Million (2023-2028)
  • Table 254. South Korea Docetaxel, by End User USD Million (2023-2028)
  • Table 255. Taiwan Docetaxel, by Type USD Million (2023-2028)
  • Table 256. Taiwan Docetaxel, by Application USD Million (2023-2028)
  • Table 257. Taiwan Docetaxel, by End User USD Million (2023-2028)
  • Table 258. Australia Docetaxel, by Type USD Million (2023-2028)
  • Table 259. Australia Docetaxel, by Application USD Million (2023-2028)
  • Table 260. Australia Docetaxel, by End User USD Million (2023-2028)
  • Table 261. Rest of Asia-Pacific Docetaxel, by Type USD Million (2023-2028)
  • Table 262. Rest of Asia-Pacific Docetaxel, by Application USD Million (2023-2028)
  • Table 263. Rest of Asia-Pacific Docetaxel, by End User USD Million (2023-2028)
  • Table 264. Europe Docetaxel, by Country USD Million (2023-2028)
  • Table 265. Europe Docetaxel, by Type USD Million (2023-2028)
  • Table 266. Europe Docetaxel, by Application USD Million (2023-2028)
  • Table 267. Europe Docetaxel, by End User USD Million (2023-2028)
  • Table 268. Germany Docetaxel, by Type USD Million (2023-2028)
  • Table 269. Germany Docetaxel, by Application USD Million (2023-2028)
  • Table 270. Germany Docetaxel, by End User USD Million (2023-2028)
  • Table 271. France Docetaxel, by Type USD Million (2023-2028)
  • Table 272. France Docetaxel, by Application USD Million (2023-2028)
  • Table 273. France Docetaxel, by End User USD Million (2023-2028)
  • Table 274. Italy Docetaxel, by Type USD Million (2023-2028)
  • Table 275. Italy Docetaxel, by Application USD Million (2023-2028)
  • Table 276. Italy Docetaxel, by End User USD Million (2023-2028)
  • Table 277. United Kingdom Docetaxel, by Type USD Million (2023-2028)
  • Table 278. United Kingdom Docetaxel, by Application USD Million (2023-2028)
  • Table 279. United Kingdom Docetaxel, by End User USD Million (2023-2028)
  • Table 280. Netherlands Docetaxel, by Type USD Million (2023-2028)
  • Table 281. Netherlands Docetaxel, by Application USD Million (2023-2028)
  • Table 282. Netherlands Docetaxel, by End User USD Million (2023-2028)
  • Table 283. Rest of Europe Docetaxel, by Type USD Million (2023-2028)
  • Table 284. Rest of Europe Docetaxel, by Application USD Million (2023-2028)
  • Table 285. Rest of Europe Docetaxel, by End User USD Million (2023-2028)
  • Table 286. MEA Docetaxel, by Country USD Million (2023-2028)
  • Table 287. MEA Docetaxel, by Type USD Million (2023-2028)
  • Table 288. MEA Docetaxel, by Application USD Million (2023-2028)
  • Table 289. MEA Docetaxel, by End User USD Million (2023-2028)
  • Table 290. Middle East Docetaxel, by Type USD Million (2023-2028)
  • Table 291. Middle East Docetaxel, by Application USD Million (2023-2028)
  • Table 292. Middle East Docetaxel, by End User USD Million (2023-2028)
  • Table 293. Israel Docetaxel, by Type USD Million (2023-2028)
  • Table 294. Israel Docetaxel, by Application USD Million (2023-2028)
  • Table 295. Israel Docetaxel, by End User USD Million (2023-2028)
  • Table 296. Africa Docetaxel, by Type USD Million (2023-2028)
  • Table 297. Africa Docetaxel, by Application USD Million (2023-2028)
  • Table 298. Africa Docetaxel, by End User USD Million (2023-2028)
  • Table 299. North America Docetaxel, by Country USD Million (2023-2028)
  • Table 300. North America Docetaxel, by Type USD Million (2023-2028)
  • Table 301. North America Docetaxel, by Application USD Million (2023-2028)
  • Table 302. North America Docetaxel, by End User USD Million (2023-2028)
  • Table 303. United States Docetaxel, by Type USD Million (2023-2028)
  • Table 304. United States Docetaxel, by Application USD Million (2023-2028)
  • Table 305. United States Docetaxel, by End User USD Million (2023-2028)
  • Table 306. Canada Docetaxel, by Type USD Million (2023-2028)
  • Table 307. Canada Docetaxel, by Application USD Million (2023-2028)
  • Table 308. Canada Docetaxel, by End User USD Million (2023-2028)
  • Table 309. Mexico Docetaxel, by Type USD Million (2023-2028)
  • Table 310. Mexico Docetaxel, by Application USD Million (2023-2028)
  • Table 311. Mexico Docetaxel, by End User USD Million (2023-2028)
  • Table 312. Docetaxel Sales: by Type(ml)
  • Table 313. Docetaxel Sales 40 mg/ml , by Region ml (2023-2028)
  • Table 314. Docetaxel Sales 20 mg/ml , by Region ml (2023-2028)
  • Table 315. Docetaxel Sales 10 mg/ml , by Region ml (2023-2028)
  • Table 316. Docetaxel Sales: by Application(ml)
  • Table 317. Docetaxel Sales Breast Cancer , by Region ml (2023-2028)
  • Table 318. Docetaxel Sales Non-Small Cell Lung Cancer , by Region ml (2023-2028)
  • Table 319. Docetaxel Sales Prostate Cancer , by Region ml (2023-2028)
  • Table 320. Docetaxel Sales Gastric Adenocarcinoma Cancer , by Region ml (2023-2028)
  • Table 321. Docetaxel Sales Head and Neck Cancer , by Region ml (2023-2028)
  • Table 322. Docetaxel Sales: by End User(ml)
  • Table 323. Docetaxel Sales Hospitals and Specialty Clinics , by Region ml (2023-2028)
  • Table 324. Docetaxel Sales Cancer Research and Treatment Centers , by Region ml (2023-2028)
  • Table 325. Docetaxel Sales Ambulatory Surgery Centers , by Region ml (2023-2028)
  • Table 326. South America Docetaxel Sales, by Country ml (2023-2028)
  • Table 327. South America Docetaxel Sales, by Type ml (2023-2028)
  • Table 328. South America Docetaxel Sales, by Application ml (2023-2028)
  • Table 329. South America Docetaxel Sales, by End User ml (2023-2028)
  • Table 330. Brazil Docetaxel Sales, by Type ml (2023-2028)
  • Table 331. Brazil Docetaxel Sales, by Application ml (2023-2028)
  • Table 332. Brazil Docetaxel Sales, by End User ml (2023-2028)
  • Table 333. Argentina Docetaxel Sales, by Type ml (2023-2028)
  • Table 334. Argentina Docetaxel Sales, by Application ml (2023-2028)
  • Table 335. Argentina Docetaxel Sales, by End User ml (2023-2028)
  • Table 336. Rest of South America Docetaxel Sales, by Type ml (2023-2028)
  • Table 337. Rest of South America Docetaxel Sales, by Application ml (2023-2028)
  • Table 338. Rest of South America Docetaxel Sales, by End User ml (2023-2028)
  • Table 339. Asia Pacific Docetaxel Sales, by Country ml (2023-2028)
  • Table 340. Asia Pacific Docetaxel Sales, by Type ml (2023-2028)
  • Table 341. Asia Pacific Docetaxel Sales, by Application ml (2023-2028)
  • Table 342. Asia Pacific Docetaxel Sales, by End User ml (2023-2028)
  • Table 343. China Docetaxel Sales, by Type ml (2023-2028)
  • Table 344. China Docetaxel Sales, by Application ml (2023-2028)
  • Table 345. China Docetaxel Sales, by End User ml (2023-2028)
  • Table 346. Japan Docetaxel Sales, by Type ml (2023-2028)
  • Table 347. Japan Docetaxel Sales, by Application ml (2023-2028)
  • Table 348. Japan Docetaxel Sales, by End User ml (2023-2028)
  • Table 349. India Docetaxel Sales, by Type ml (2023-2028)
  • Table 350. India Docetaxel Sales, by Application ml (2023-2028)
  • Table 351. India Docetaxel Sales, by End User ml (2023-2028)
  • Table 352. South Korea Docetaxel Sales, by Type ml (2023-2028)
  • Table 353. South Korea Docetaxel Sales, by Application ml (2023-2028)
  • Table 354. South Korea Docetaxel Sales, by End User ml (2023-2028)
  • Table 355. Taiwan Docetaxel Sales, by Type ml (2023-2028)
  • Table 356. Taiwan Docetaxel Sales, by Application ml (2023-2028)
  • Table 357. Taiwan Docetaxel Sales, by End User ml (2023-2028)
  • Table 358. Australia Docetaxel Sales, by Type ml (2023-2028)
  • Table 359. Australia Docetaxel Sales, by Application ml (2023-2028)
  • Table 360. Australia Docetaxel Sales, by End User ml (2023-2028)
  • Table 361. Rest of Asia-Pacific Docetaxel Sales, by Type ml (2023-2028)
  • Table 362. Rest of Asia-Pacific Docetaxel Sales, by Application ml (2023-2028)
  • Table 363. Rest of Asia-Pacific Docetaxel Sales, by End User ml (2023-2028)
  • Table 364. Europe Docetaxel Sales, by Country ml (2023-2028)
  • Table 365. Europe Docetaxel Sales, by Type ml (2023-2028)
  • Table 366. Europe Docetaxel Sales, by Application ml (2023-2028)
  • Table 367. Europe Docetaxel Sales, by End User ml (2023-2028)
  • Table 368. Germany Docetaxel Sales, by Type ml (2023-2028)
  • Table 369. Germany Docetaxel Sales, by Application ml (2023-2028)
  • Table 370. Germany Docetaxel Sales, by End User ml (2023-2028)
  • Table 371. France Docetaxel Sales, by Type ml (2023-2028)
  • Table 372. France Docetaxel Sales, by Application ml (2023-2028)
  • Table 373. France Docetaxel Sales, by End User ml (2023-2028)
  • Table 374. Italy Docetaxel Sales, by Type ml (2023-2028)
  • Table 375. Italy Docetaxel Sales, by Application ml (2023-2028)
  • Table 376. Italy Docetaxel Sales, by End User ml (2023-2028)
  • Table 377. United Kingdom Docetaxel Sales, by Type ml (2023-2028)
  • Table 378. United Kingdom Docetaxel Sales, by Application ml (2023-2028)
  • Table 379. United Kingdom Docetaxel Sales, by End User ml (2023-2028)
  • Table 380. Netherlands Docetaxel Sales, by Type ml (2023-2028)
  • Table 381. Netherlands Docetaxel Sales, by Application ml (2023-2028)
  • Table 382. Netherlands Docetaxel Sales, by End User ml (2023-2028)
  • Table 383. Rest of Europe Docetaxel Sales, by Type ml (2023-2028)
  • Table 384. Rest of Europe Docetaxel Sales, by Application ml (2023-2028)
  • Table 385. Rest of Europe Docetaxel Sales, by End User ml (2023-2028)
  • Table 386. MEA Docetaxel Sales, by Country ml (2023-2028)
  • Table 387. MEA Docetaxel Sales, by Type ml (2023-2028)
  • Table 388. MEA Docetaxel Sales, by Application ml (2023-2028)
  • Table 389. MEA Docetaxel Sales, by End User ml (2023-2028)
  • Table 390. Middle East Docetaxel Sales, by Type ml (2023-2028)
  • Table 391. Middle East Docetaxel Sales, by Application ml (2023-2028)
  • Table 392. Middle East Docetaxel Sales, by End User ml (2023-2028)
  • Table 393. Israel Docetaxel Sales, by Type ml (2023-2028)
  • Table 394. Israel Docetaxel Sales, by Application ml (2023-2028)
  • Table 395. Israel Docetaxel Sales, by End User ml (2023-2028)
  • Table 396. Africa Docetaxel Sales, by Type ml (2023-2028)
  • Table 397. Africa Docetaxel Sales, by Application ml (2023-2028)
  • Table 398. Africa Docetaxel Sales, by End User ml (2023-2028)
  • Table 399. North America Docetaxel Sales, by Country ml (2023-2028)
  • Table 400. North America Docetaxel Sales, by Type ml (2023-2028)
  • Table 401. North America Docetaxel Sales, by Application ml (2023-2028)
  • Table 402. North America Docetaxel Sales, by End User ml (2023-2028)
  • Table 403. United States Docetaxel Sales, by Type ml (2023-2028)
  • Table 404. United States Docetaxel Sales, by Application ml (2023-2028)
  • Table 405. United States Docetaxel Sales, by End User ml (2023-2028)
  • Table 406. Canada Docetaxel Sales, by Type ml (2023-2028)
  • Table 407. Canada Docetaxel Sales, by Application ml (2023-2028)
  • Table 408. Canada Docetaxel Sales, by End User ml (2023-2028)
  • Table 409. Mexico Docetaxel Sales, by Type ml (2023-2028)
  • Table 410. Mexico Docetaxel Sales, by Application ml (2023-2028)
  • Table 411. Mexico Docetaxel Sales, by End User ml (2023-2028)
  • Table 412. Docetaxel: by Type(USD/Units)
  • Table 413. Research Programs/Design for This Report
  • Table 414. Key Data Information from Secondary Sources
  • Table 415. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Docetaxel: by Type USD Million (2017-2022)
  • Figure 5. Global Docetaxel: by Application USD Million (2017-2022)
  • Figure 6. Global Docetaxel: by End User USD Million (2017-2022)
  • Figure 7. South America Docetaxel Share (%), by Country
  • Figure 8. Asia Pacific Docetaxel Share (%), by Country
  • Figure 9. Europe Docetaxel Share (%), by Country
  • Figure 10. MEA Docetaxel Share (%), by Country
  • Figure 11. North America Docetaxel Share (%), by Country
  • Figure 12. Global Docetaxel: by Type ml (2017-2022)
  • Figure 13. Global Docetaxel: by Application ml (2017-2022)
  • Figure 14. Global Docetaxel: by End User ml (2017-2022)
  • Figure 15. South America Docetaxel Share (%), by Country
  • Figure 16. Asia Pacific Docetaxel Share (%), by Country
  • Figure 17. Europe Docetaxel Share (%), by Country
  • Figure 18. MEA Docetaxel Share (%), by Country
  • Figure 19. North America Docetaxel Share (%), by Country
  • Figure 20. Global Docetaxel: by Type USD/Units (2017-2022)
  • Figure 21. Global Docetaxel share by Players 2022 (%)
  • Figure 22. Global Docetaxel share by Players (Top 3) 2022(%)
  • Figure 23. Global Docetaxel share by Players (Top 5) 2022(%)
  • Figure 24. BCG Matrix for key Companies
  • Figure 25. Sanofi-Aventis (France) Revenue, Net Income and Gross profit
  • Figure 26. Sanofi-Aventis (France) Revenue: by Geography 2022
  • Figure 27. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 28. Pfizer (United States) Revenue: by Geography 2022
  • Figure 29. Teva Pharmaceutical Industries (Israel) Revenue, Net Income and Gross profit
  • Figure 30. Teva Pharmaceutical Industries (Israel) Revenue: by Geography 2022
  • Figure 31. Taj Pharmaceuticals (India) Revenue, Net Income and Gross profit
  • Figure 32. Taj Pharmaceuticals (India) Revenue: by Geography 2022
  • Figure 33. Dr. Reddy's Laboratories (India) Revenue, Net Income and Gross profit
  • Figure 34. Dr. Reddy's Laboratories (India) Revenue: by Geography 2022
  • Figure 35. Sandoz (Germany) Revenue, Net Income and Gross profit
  • Figure 36. Sandoz (Germany) Revenue: by Geography 2022
  • Figure 37. Actavis (United States) Revenue, Net Income and Gross profit
  • Figure 38. Actavis (United States) Revenue: by Geography 2022
  • Figure 39. Sun pharma (India) Revenue, Net Income and Gross profit
  • Figure 40. Sun pharma (India) Revenue: by Geography 2022
  • Figure 41. Beijing Union Pharmaceutical Factory (China) Revenue, Net Income and Gross profit
  • Figure 42. Beijing Union Pharmaceutical Factory (China) Revenue: by Geography 2022
  • Figure 43. Accord Healthcare (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 44. Accord Healthcare (United Kingdom) Revenue: by Geography 2022
  • Figure 45. Global Docetaxel: by Type USD Million (2023-2028)
  • Figure 46. Global Docetaxel: by Application USD Million (2023-2028)
  • Figure 47. Global Docetaxel: by End User USD Million (2023-2028)
  • Figure 48. South America Docetaxel Share (%), by Country
  • Figure 49. Asia Pacific Docetaxel Share (%), by Country
  • Figure 50. Europe Docetaxel Share (%), by Country
  • Figure 51. MEA Docetaxel Share (%), by Country
  • Figure 52. North America Docetaxel Share (%), by Country
  • Figure 53. Global Docetaxel: by Type ml (2023-2028)
  • Figure 54. Global Docetaxel: by Application ml (2023-2028)
  • Figure 55. Global Docetaxel: by End User ml (2023-2028)
  • Figure 56. South America Docetaxel Share (%), by Country
  • Figure 57. Asia Pacific Docetaxel Share (%), by Country
  • Figure 58. Europe Docetaxel Share (%), by Country
  • Figure 59. MEA Docetaxel Share (%), by Country
  • Figure 60. North America Docetaxel Share (%), by Country
  • Figure 61. Global Docetaxel: by Type USD/Units (2023-2028)
List of companies from research coverage that are profiled in the study
  • Sanofi-Aventis (France)
  • Pfizer (United States)
  • Teva Pharmaceutical Industries (Israel)
  • Taj Pharmaceuticals (India)
  • Dr. Reddy's Laboratories (India)
  • Sandoz (Germany)
  • Actavis (United States)
  • Sun pharma (India)
  • Beijing Union Pharmaceutical Factory (China)
  • Accord Healthcare (United Kingdom)
Additional players considered in the study are as follows:
Jiangsu Hengrui (China) , Eagle Pharmaceuticals (United States)
Select User Access Type

Key Highlights of Report


Dec 2023 215 Pages 51 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Docetaxel Market Quantitative research analysis
Global Docetaxel Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Historical year: 2018-2022; Base year: 2022; Forecast period: 2023 to 2028
Companies that are profiled in Global Docetaxel Market are Sanofi-Aventis (France), Pfizer (United States), Teva Pharmaceutical Industries (Israel), Taj Pharmaceuticals (India), Dr. Reddy's Laboratories (India), Sandoz (Germany), Actavis (United States), Sun pharma (India), Beijing Union Pharmaceutical Factory (China) and Accord Healthcare (United Kingdom) etc.
Breast Cancer segment in Global market to hold robust market share owing to "Rise in Number of Patients Suffering With Cancer ".
AMA Research predicts that United States and Indian Players will contribute to the maximum growth of Global Docetaxel market throughout the forecasted period.

Know More About Global Docetaxel Market Report?

Have a Query? Click Here

Other Related Reports

Doxorubicin Comprehensive Study by Type (Lyophilized Powder, Doxorubicin Injection), Application (Ovarian, Multiple Myeloma, Kaposi Sarcoma, Leukemia, Bone Sarcoma, Breast Cancer, Gastric Cancer, Oth...
$ 3450
Bone Substitutes Comprehensive Study by Type (Bone Grafts {Autograft, Allograft, Xenograft}, Ceramics {Hydroxyapatite, Tricalcium Phosphate (TCP), Calcium Sulphate}, Growth Factors {Demineralized Bon...
$ 3750
Latanoprost Comprehensive Study by Type (Brand Drug, Generic Drug), Application (Open-angle Glaucoma, Close-angle Glaucoma), End Users (Pediatrics, Adults, Geriatrics), Bottle Size (2.5 ml, 5 ml, Oth...
$ 3500
Aspirin Comprehensive Study by Type (99.5% Purity, 99% Purity, Others), Application (Tablets Product, Capsule Product, Others), End-User (Hospitals, Ambulatory Surgical Center (ASC), Others) Players ...
$ 3500
First Aid Comprehensive Study by Type (Adhesive Bandages, Gauses, Disinfectants, Others), Application (Clinic, Hospital, Home Use) Players and Region - Global Market Outlook to 2030
$ 3500
Glucosamine and Chondroitin Sulfate Comprehensive Study by Application (Pharmaceutical, Dietary Supplements (Animal Feed, Nutraceuticals), Cosmetics, Others), Source (Bovine, Swine, Poultry, Shark, S...
$ 3500